Forte Biosciences Files Definitive Proxy Statement

TL;DR

Forte Bio (FBRX) filed its proxy statement. Shareholders, pay attention to voting items.

AI Summary

Forte Biosciences, Inc. filed its definitive proxy statement on December 31, 2024, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A, concerns the company's proxy solicitation materials. The company's principal executive offices are located at 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247.

Why It Matters

This filing is crucial for shareholders as it outlines important information regarding upcoming shareholder meetings, voting matters, and executive compensation, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine filing of a proxy statement, which is standard for publicly traded companies and does not inherently indicate new risks.

Key Players & Entities

• Forte Biosciences, Inc. (company) — Registrant
• 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247 (location) — Business and Mail Address
• Tocagen Inc (company) — Former Company Name

FAQ

Key Financial Figures

• $8,000 — es from stockholders for a fee of up to $8,000 plus certain additional costs associate
• $53.0 m — acement financing for gross proceeds of $53.0 million, pursuant to which we issued 4,93

Filing Documents

• d806362ddef14a.htm (DEF 14A) — 393KB
• g806362g04x96.jpg (GRAPHIC) — 4KB
• g806362g19n78.jpg (GRAPHIC) — 18KB
• g806362g26k02.jpg (GRAPHIC) — 30KB
• 0001193125-24-287177.txt ( ) — 466KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 21 Processes and Procedures for Compensation Decisions 21 Employment Arrangements 22 Outstanding Equity Awards at Fiscal 2023 Year-End 24

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26 OTHER MATTERS 30 Table of Contents FORTE BIOSCIENCES, INC. PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS To be held at 8:00 a.m., Central Time, on Friday, January 24, 2025 The information provided in the question and answer format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully. QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR SPECIAL MEETING Why am I receiving these materials? This proxy statement and the form of proxy are furnished in connection with the solicitation of proxies by our Board of Directors (the Board) for use at the Special Meeting of stockholders of Forte Biosciences, Inc. (the Company or Forte), a Delaware corporation, and any postponements, adjournments or continuations thereof. The Special Meeting will be held on Friday, January 24, 2025, at 8:00 a.m., Central Time. The Special Meeting will be conducted virtually via live audio webcast. You will be able to attend the Special Meeting virtually by visiting www.virtualshareholdermeeting.com/FBRX2025SM, where you will be able to listen to the meeting live and vote online during the meeting. What proposal will be voted on at the Special Meeting? One proposal will be voted on at the Special Meeting: the approval of an amended and restated 2021 Equity Incentive Plan. How does the Board recommend that I vote on this proposal? Our Board recommends that you vote your shares: FOR the approval of an amended and restated 2021 Equity Incentive Plan. WHO IS ENTITLED TO VOTE AT THE SPECIAL MEETING? Holders of our Common Stock as of the close of business on December 30, 2024, the record date for the Special Meeting, may vote at the Special Meeting. As of the record date, there were 6,393,323 shares of our Common Stock outstanding. Each share of Common Stock is entitled to one vot

View Full Filing

View this DEF 14A filing on SEC EDGAR